Synchron Raises US$200 Million in Series D Financing to Advance BCI Technology
Synchron has secured US$200 million in a Series D financing round. The funds will accelerate commercialisation of the company’s first-generation Stentrode brain-computer interface (BCI) platform and support development of a "next-generation, transcatheter, high-channel whole-brain interface."
Funding Use and Company Plans
The investment will speed up pivotal trials and preparations for the commercial launch of the Stentrode BCI system. According to a company press release, this Series D round will also enable Synchron to expand its team by hiring engineers, neuroscientists, and operators to advance the next generation of BCIs.
Investors and Total Funding
- The round was led by Double Point Ventures, with participation from existing investors including ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, and METIS.
- New investors include the Australian National Reconstruction Fund (NRF), T Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, and IQT.
This latest financing brings Synchron's total capital raised to US$345 million.
Synchron stated in its press release: "Bolstered by this Series D funding, we will continue hiring engineers, neuroscientists and operators to advance the next generation of BCIs."
Author's summary: Synchron's significant new funding round accelerates the rollout of its Stentrode BCI platform and drives innovation in advanced brain-computer interface technology.